¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"diastolic shock"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mid-diastolic
    È®ÀåÁß±â-
  • mid-diastolic murmur
    È®ÀåÁß±âÀâÀ½
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀüÀ§
  • anaphylactic shock
    ¾Æ³ªÇʶô½Ã½º¼îÅ©
  • circulatory shock
    ¼øÈ¯¼îÅ©
  • cold shock
    ÇÑ·©¼îÅ©
  • counter shock
    ¸ÂÃæ°Ý, ¿ªÃæ°Ý
  • culture shock
    ¹®È­Ãæ°Ý
  • cardiogenic shock
    ½ÉÀ强¼îÅ©
  • extracorporeal shock wave lithotripsy
    ü¿ÜÃæ°ÝÆÄ¼â¼®(¼ú), ¸ö¹ÛÃæ°ÝÆÄµ¹±þ¼ú
  • electric shock
    Àü±âÃæ°Ý
  • electric shock therapy
    Àü±âÃæ°Ý¿ä¹ý
  • endotoxin shock
    ³»µ¶¼Ò¼îÅ©
  • hypoglycemic shock
    ÀúÇ÷´ç¼îÅ©
  • hypoglycemic shock therapy
    ÀúÇ÷´çÃæ°Ý¿ä¹ý, Àν¶¸°Ãæ°Ý¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀüÀ§
  • mid-diastolic murmur
    È®ÀåÁß±âÀâÀ½
  • anaphylactic shock
    ¾Æ³ªÇʶô½Ã½º¼îÅ©, Ãʰú¹Î¹ÝÀÀ¼îÅ©
  • shock absorber
    Ãæ°Ý¿ÏÃæ±â
  • bacterial shock
    ¼¼±Õ¼îÅ©
  • cardiogenic shock
    ½ÉÀ强¼îÅ©, ½ÉÀåÅ¿¼îÅ©
  • circulatory shock
    ¼øÈ¯¼îÅ©
  • cold shock
    ÇÑ·©¼îÅ©
  • convulsive shock therapy
    °æ·ÃÃæ°Ý¿ä¹ý
  • counter shock
    ¸ÂÃæ°Ý
  • culture shock
    ¹®È­Ãæ°Ý
  • direct current shock
    Á÷·ùÀü°Ý¼îÅ©
  • dye shock
    »ö¼ÒÃæ°Ý
  • electric shock
    Àü±âÃæ°Ý
  • electric shock therapy
    Àü±âÃæ°Ý¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemorrhagic shock
    ÃâÇ÷¼º¼ï
  • hyperglycemic shock
    °íÇ÷´ç¼º ¼ï.
  • hypovolemic shock
    (¼øÈ¯)Ç÷¾×·®°¨¼Ò¼º¼ï.
  • hypovolemic shock
    (¼øÈ¯)Ç÷¾×·®°¨¼Ò¼º¼ï
  • induced shock
    À¯µµ(ë¯Óô)¼ï.
  • induction shock
    À¯µµ¼ï.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
  • post electric shock syndrome
    Àü°Ý(ï³Ìª)¼ïÈÄÁõÈıº(¡­ý­ñøý¦ÏØ)
  • postelectric shock syndrome
    Àü°Ý¼ïÈÄÁõÈıº.
  • postoperative shock
    (¼ö)¼úÈļï.
  • postoperative shock
    (¼ö)¼úÈļï((â¢)âúý­¡­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diastolic reserve
    È®Àå±âº¸À¯·®.
  • diastolic rumble
    È®Àå±â±¼¸²<ÀâÀ½>.
  • diastolic rumble
    È®Àå±â¿ï¸²<ÀâÀ½>.
  • diastolic standstill
    È®Àå±â(½É)Á¤Áö(¡­ãýïÎò­).
  • diastolic thrill
    È®Àå±âÁøÀü(¡­òèïµ), È®Àå±âÁøµ¿.
  • diastolic trough
    È®Àå°îÀú.
  • diastolic volume
    È®Àå±â¿ëÀû(¡­é»îÝ).
  • early diastolic murmur =protodiastolic m.
    Á¶±âÈ®ÀåÃʱâÀâÀ½(ðÄÑ¢üªíåôøÑ¢íÚëå).
  • early diastolic murmur =protodiastolic m.
    È®ÀåÃʱâ½ÉÀâÀ½.
  • end-diastolic pressure
    È®Àå±â¸»¾Ð(üªíåÐñØÇäâ)
  • end-diastolic volume
    È®Àå±â¸»¿ëÀû(¡­éÄîÝ)
  • left ventricular end-diastolic pressure
    Á½ɽÇÀ̿ϱ⸻¾Ð
  • left ventricular end-diastolic volume
    Á½ɽÇÀ̿ϱ⸻¿ëÀû
  • left ventricular end-diastolic volume
    Á½ɽÇÈ®À帻±â¿ëÀû(¡­üªíåØÇÑ¢é»îÝ).
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀü¾Ð(õÌÓÞì¬èÐÑ¢ï³äâ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EST(?) Electric(Electro-) Shock Theraphy; Àü±â Ãæ°ÝÄ¡·á
  = ECT
ESWL Extracorporeal Shock-Wave Lithotripsy
  - Ix for Gall Stone
    ...
TSS Toxic Shock Syndrome
TSST-1 Toxic Shock Syndrome Toxin-1
  = Enterotoxin type F
CGS cardiogenic shock; catgut suture
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DP Diastolic pressure
EDV End Diastolic Volume
EDV End diastolic
EDA End diastolic area
EDP End diastolic pressure
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • semi-shock
    ¹Ý¼îÅ©
    ´ë»ó ±â±¸°¡ ÀÛ¿ëÇØ, °Ü¿ì ¼îÅ©¸¦ ¸éÇÏ´Â °æ¿ì.
  • shock
    ¼ï
    1. ½Åü ÆòÇüÀÇ °©ÀÛ½º·¯¿î Àå¾Ö. 2. ÁÖ¿ä Àå±â¿¡ ´ëÇÑ Ç÷·ù À¯Áö¸¦ À§ÇÑ ¼øÈ¯°èÀÇ, ±â´É »ó½Ç·Î Ư¡ Áö¿öÁö´Â ½É°¢ÇÑ Ç÷¾× ¼øÈ¯°ú ´ë»çÀÇ ¹æÇØ Á¶°Ç. ÀÌ´Â Ç÷¾×·®ÀÇ ÀúÇÏ·Î ¹ß»ýÇÒ ¼öµµ ÀÖ°í, ½É±â´É ÀúÇÏ È¤Àº ºñÁ¤»óÀûÀÎ vasomotor toneÀ¸·Î ÀÎÇÑ °æ¿ìµµ ÀÖ´Ù. ÀúÇ÷¾Ð, ÇǺÎÀÇ ÇÑ·©, Åë»óÀº ºó¸Æ, Á¾Á¾ ºÒ¾ÈÀ» Ư¡À¸·Î ÇÑ´Ù.
  • shock circuit reaction
    ´Ü¶ô ¹ÝÀÀ
    °¨Á¤Àû Ãæµ¿ÀÌ À̼ºÀÇ ÅëÁ¦¸¦ ¹þ¾î³ª Á÷Á¢À¸·Î Çൿ¿¡ ¿Å°ÜÁö´Â ¹ÝÀÀ.
  • shock kidney
    ¼îÅ©¼º ½Å ±â´É Àå¾Ö
    ¼îÅ©¿¡ ºüÁ® Ç÷¾Ð ÀúÇϰ¡ ±æ°Ô À̾îÁ® ½Å Ç÷·ù·®ÀÌ °¨¼ÒÇÏ¿© »ý±ä ±Þ¼º ½Å ºÎÀü.
  • shock lung
    ¼îÅ© Æó
    ÃâÇ÷¼º ¼îÅ© µî¿¡ ÇÕº´Çϴ ȣÈí ºÎÀü.
  • shock position
    ¼ï À§Ä¡
    ȯÀÚ°¡ ¼îÅ©¸¦ ÀÏÀ¸Ä×À» ¶§ ±× ±¸±Þ üÀ§·Î¼­ ÃëÇØÁö´Â üÀ§.
  • shock shortening heat
    ´ÜÃà ¿­
    ´ÜÃàÇÏ´Â ±æÀÌ¿¡ ºñ·ÊÇØ ºÎÇÏ¿¡ °ü°è¾øÀÌ ¹ß»ýÇÏ´Â ¿­.
  • shock term memory
    ´Ü±â ±â¾ï
  • shock treatment
    ¼ï Ä¡·á
    Ä«¸£µð¾ÆÁ¹ °æ·Ã ¿ä¹ý, Àü±â ¼îÅ© ¿ä¹ý, Àν¶¸° ¼îÅ© ¿ä¹ý µîÀÌ ÀÖ´Ù.
  • shock wave imaging
    Ãæ°ÝÆÄ »ó
  • state of shock
    Ãæ°Ý »óÅÂ
  • wound shock
    ¿Ü»ó¼º ¼ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
break shock The shock produced by breaking a constant current passing through the body.
(05 Mar 2000)
cardiac shock A form of shock (inadequate delivery of oxygen to the tissues) that occurs secondary to the weakened pumping function of the heart. This condition may be precipitated by myocardial infarction or cardiomyopathy.
Treatment includes fluid restriction, diuretics, vasopressors (dopamine) to support the blood pressure and the use of intravenous medications (dobutamine) which stimulate the heart to contract more forcefully.
(27 Sep 1997)
cardiogenic shock A form of shock (inadequate delivery of oxygen to the tissues) that occurs secondary to the weakened pumping function of the heart. This condition may be precipitated by myocardial infarction or cardiomyopathy.
Treatment includes fluid restriction, diuretics, vasopressors (dopamine) to support the blood pressure and the use of intravenous medications (dobutamine) which stimulate the heart to contract more forcefully.
(27 Sep 1997)
cardiopulmonary obstructive shock <cardiology> This term describes a number of conditions that involve a severe disturbance of the cardiopulmonary circuit resulting in shock (inadequate delivery of oxygen to the tissues).
Examples include: pulmonary embolism, pericardial tamponade, pneumothorax and constrictive pericarditis.
(27 Sep 1997)
vasogenic shock Shock resulting from depressed activity of the higher vasomotor centres in the brain stem and the medulla, producing vasodilation without loss of fluid so that the container is disproportionately large. In oligaemic shock, blood volume is reduced; in both, return of venous blood is inadequate.
(05 Mar 2000)
reversible shock Shock that will respond to treatment and from which recovery is possible.
(05 Mar 2000)
chronic shock The state of peripheral circulatory insufficiency developing in elderly patients with a debilitating disease, e.g., carcinoma; a subnormal blood volume makes the patient susceptible to haemorrhagic shock as a result of even a moderate blood loss such as may occur during an operation.
(05 Mar 2000)
wet shock A severe condition that occurs when the level of blood glucose (sugar) drops quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough.
See: hypoglycaemia.
(09 Oct 1997)
cultural shock A form of stress associated with the beginning of an individual's assimilation into a new culture vastly different from that in which he or she was raised.
(05 Mar 2000)
haemorrhagic shock Hypovolaemic shock resulting from acute haemorrhage, characterised by hypotension, tachycardia, pale, cold, and clammy skin, and oliguria.
(05 Mar 2000)
primary shock Shock mainly nervous in nature, from pain, anxiety, etc., which ensues almost immediately upon the receipt of a severe injury.
(05 Mar 2000)
heat-shock factor <cell biology, protein> A class of molecular chaperones found in both prokaryotes and in several compartments of eukaryotic cells. There is evidence that these proteins can interact with polypeptides during a variety of assembly processes in such a way as to prevent the formation of nonfunctional structures.
(12 Dec 1998)
Previous: heat-shock factor, heat-shock gene, heat-shock protein, heat-shock protein 27 kinaseNext: heat-shock proteins 90, heat-shock responseheat-shock factor -->heat-shock proteins 90
<cell biology, protein> A class of molecular chaperones whose members act in the mechanism of signal transduction by steroid receptors.
(12 Dec 1998)
heat-shock gene <molecular biology> A set of genes present in most animals which are transcribed suddenly, quickly, and with coordination when the animal is exposed to certain types of stress such as a sudden temperature increase.
(09 Oct 1997)
heat-shock protein <cell biology, molecular biology, protein> Families of proteins conserved through prokaryotic and eukaryotic cells and bacteria in response to hyperthermia and other environmental stresses, although some are constitutively expressed. They increase thermal tolerance and perform functions essential to cell survival under these conditions.
Some serve to stabilise proteins in abnormal configurations, play a role in folding and unfolding of proteins and the assembly of oligomeric complexes and may act as chaperonins. Hsp90 complexes with inactive steroid hormone receptor and is displaced upon ligand binding.
Four major sub classes are recognised: hsp90, hsp70, hsp60 and small hsps. Hsps have been suggested to act as major immunogens in many infections.
Acronym: HSP
(12 Dec 1998)
heat-shock protein 27 kinase <enzyme> Phosphorylates hsp 26 on serine residues when stimulated by tumour necrosis factor or interleukin 1
Registry number: EC 2.7.1.-
Synonym: hsp 27 kinase, heat-shock protein 27 kinase, hsp27 kinase
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • shock absorber
    ¿ÏÃæ±â
  • shock action
    Ãæ°Ý
  • shock dog
    »ð»ì°³
  • shock stall
    Ãæ°ÝÆÄ ½Ç¼Ó
  • shock therapy
    (Á¤½Åº´ÀÇ)Ãæ°Ý(Àü°Ý)¿ä¹ý
  • shock troops
    Ư°ø´ë
  • shock wave
    Ãæ°ÝÆÄ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á